News Image

Which stocks are moving before the opening bell on Tuesday?

By Mill Chart

Last update: Apr 16, 2024

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

Pre-market gainers

TickerChangeComment
WISA74.86%Exciting news for WISA TECHNOLOGIES INC (NASDAQ:WISA) as their shares soared 74.86% to $3.06 during the pre-market session on Tuesday. After recording a 11.0K% gain in the previous session, NASDAQ:WISA maintains its positive trajectory in today's pre-market, with an additional 74.86% increase.
DFLI55.56%During Tuesday's pre-market session, DRAGONFLY ENERGY HOLDINGS CO (NASDAQ:DFLI) exhibited strong growth, with the stock price climbing 55.56% to $0.7. A press release (Dragonfly Energy Reports Fourth Quarter 2023 and Full Year Financial Results) was released yesterday.
BRTX28.03%During Tuesday's pre-market session, BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) exhibited strong growth, with the stock price climbing 28.03% to $1.69. The stock is trading 32.31% lower than 6 months ago.
HOLOW27.23%During Tuesday's pre-market trading, GOLDEN PATH ACQ -CW28 (NASDAQ:HOLOW) demonstrated strong momentum, with the stock price rising 27.23% to $0.08. The stock is trading 36.15% lower than a month ago.
CGEM20.48%During Tuesday's pre-market session, CULLINAN ONCOLOGY INC (NASDAQ:CGEM) experienced a 20.48% increase, with the stock price reaching $19.94. Earlier today the company had a press release: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases.
SPCB19.93%SUPERCOM LTD's (NASDAQ:SPCB) shares surged 19.93% to reach $0.48 during the pre-market session on Tuesday. Also in the previous session NASDAQ:SPCB had a very good day: shares closed with a 45.07% gain.
XPER19.5%Exciting news for XPERI INC (NYSE:XPER) as their shares soared 19.5% to $12.07 during the pre-market session on Tuesday.
ITCI18.9%INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) experienced an impressive 18.9% increase in share price, reaching $77.0 during the pre-market session on Tuesday. The stock is trading 29.36% higher than 6 months ago.
KXIN16.67%KAIXIN HOLDINGS's (NASDAQ:KXIN) stock price increased by 16.67% to $0.17. After experiencing a decline of -18.03% yesterday, NASDAQ:KXIN shows signs of a rebound in today's pre-market session.
MKFG14.04%MARKFORGED HOLDING CORP's (NYSE:MKFG) shares rose 14.04% to $0.65. Yesterday's -14.35% decline in NYSE:MKFG has given way to a potential bounce-back as observed in today's pre-market session.

Our premarket gainers page will show you the full list.

Pre-market losers

TickerChangeComment
INO-23.75%INOVIO PHARMACEUTICALS INC's (NASDAQ:INO) shares fell 23.75% to $8.38 during Tuesday's pre-market session. Shareholders saw the stock price going 35.78% higher in the past 3 months.
CLDI-21.67%CALIDI BIOTHERAPEUTICS INC's (NYSEARCA:CLDI) shares experienced a 21.67% decline, falling to $0.47 during Tuesday's pre-market session. Following yesterday's challenging day, NYSEARCA:CLDI closed -13.64% lower during the regular session, and the negative sentiment carries over into today's pre-market session.
PACB-17.11%The pre-market session on Tuesday witnessed a 17.11% decrease in PACIFIC BIOSCIENCES OF CALIF's (NASDAQ:PACB) shares, with the stock price falling to $2.35. The negative sentiment prevails for NASDAQ:PACB as it recorded a -10.57% decline during the regular session yesterday, followed by another decline of 17.11% in today's pre-market session.
SWVLW-14.47%PIVOTAL HOLDINGS CORP -CW27's (NASDAQ:SWVLW) shares fell 14.47% to $0.02. In the last month the stock gained 65.49%.
PSTX-11.93%POSEIDA THERAPEUTICS INC's (NASDAQ:PSTX) shares fell 11.93% to $2.14 during Tuesday's pre-market session. Yesterday's drop of -10.99% continued in today's pre-market session with another decline of 11.93%
TPET-11.9%Investors observed a 11.9% decline in TRIO PETROLEUM CORP's (NYSEARCA:TPET) stock price, which now stands at $0.56 during Tuesday's pre-market session. Yesterday's 22.09% gain in NYSEARCA:TPET gives way to a 11.9% decrease in today's pre-market session, showcasing market fluctuations.
PRFX-11.31%Tuesday's pre-market session showed a 11.31% decrease in the stock price of PAINREFORM LTD (NASDAQ:PRFX), reaching $0.87. Yesterday's drop of -10.91% continued in today's pre-market session with another decline of 11.31%
INDO-10.53%During Tuesday's pre-market session, the shares of INDONESIA ENERGY CORP LTD (NYSEARCA:INDO) declined by 10.53%, reaching $5.44. Despite a promising gain of 23.08% yesterday, NYSEARCA:INDO faces downward pressure with a 10.53% decline in today's pre-market session.
DBGI-10.0%DIGITAL BRANDS GROUP INC's (NASDAQ:DBGI) stock price recorded a 10.0% decrease, falling to $3.6. The company is releasing earnings today. Shareholders saw the stock price going 25.0% higher in the past month.
ORGS-9.89%ORGENESIS INC's (NASDAQ:ORGS) shares experienced a 9.89% decline, falling to $0.45 during Tuesday's pre-market session. The stock is trading 36.68% lower than a month ago.

To see the full list of premarket losers you can use our premarket losers page.

Back

POSEIDA THERAPEUTICS INC

NASDAQ:PSTX (5/16/2024, 7:12:34 PM)

After market: 3.34 -0.01 (-0.15%)

3.345

-0.11 (-3.32%)

PSTX News

News Image2 days ago - InvestorPlacePSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024

PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image2 days ago - BusinessInsiderPSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Poseida Therapeutics (NASDAQ:PSTX) just reported results for the first quarter ...

News Image2 days ago - Poseida Therapeutics, Inc.Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell...

News Image15 days ago - Astellas Pharma Inc.Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO:...

News Imagea month ago - Poseida Therapeutics, Inc.Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for...

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!

News Imagea month ago - Poseida Therapeutics, Inc.Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

News Image2 months ago - Poseida Therapeutics, Inc.Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

News Image2 months ago - Poseida Therapeutics, Inc.Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

News Image2 months ago - Poseida Therapeutics, Inc.Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

News Image2 months ago - Poseida Therapeutics, Inc.Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

News Image2 months ago - InvestorPlacePSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023

PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

PSTX Links
Follow us for more